The successful treatment of refractory polyarteritis nodosa using infliximab

Satoko Matsuo, Keigo Hayashi, Eisaku Morimoto, Ayako Kato, Kenei Sada, Haruki Watanabe, Mariko Takano-Narazaki, Katsue Sunahori-Watanabe, Tomoko Kawabata, Jun Wada

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various immunosuppressive treatments, including cyclophosphamide, methotrexate, and rituximab. After infliximab (IFX) treatment was initiated, his symptoms improved dramatically and remission was maintained. IFX is considered to be an effective alternative treatment for PAN which proves to be refractory to several immunosuppressive treatments.

Original languageEnglish
Pages (from-to)1435-1438
Number of pages4
JournalInternal Medicine
Volume56
Issue number11
DOIs
Publication statusPublished - 2017

    Fingerprint

Keywords

  • Infliximab
  • Polyarteritis nodosa
  • Rituximab

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Matsuo, S., Hayashi, K., Morimoto, E., Kato, A., Sada, K., Watanabe, H., Takano-Narazaki, M., Sunahori-Watanabe, K., Kawabata, T., & Wada, J. (2017). The successful treatment of refractory polyarteritis nodosa using infliximab. Internal Medicine, 56(11), 1435-1438. https://doi.org/10.2169/internalmedicine.56.8235